Daniel Lee Flynn - 16 Jun 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
Chief Scientific Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 Jun 2023
Net transactions value
-$23,835
Form type
4
Filing time
21 Jun 2023, 16:05:15 UTC
Previous filing
17 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Sale $23,835 -1,655 -2.8% $14.40 57,158 16 Jun 2023 Direct F1
holding DCPH Common Stock 180,947 16 Jun 2023 By Daniel L. Flynn Revocable Trust F2
holding DCPH Common Stock 91,020 16 Jun 2023 By Daniel L. Flynn Irrevocable Trust
holding DCPH Common Stock 49,488 16 Jun 2023 By GRAT F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was to cover tax liabilities in the vesting of restricted stock units.
F2 Reflects shares previously transferred from the Daniel L. Flynn Revocable Trust to the Reporting Person's grantor retained annuity trust.